MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
Rhea-AI Summary
MetaVia (Nasdaq: MTVA) announced expanded global patent protection for vanoglipel (DA-1241), reporting 48 granted and pending patents across the U.S., Europe, Japan, China and other countries. The portfolio, exclusively licensed from Dong-A ST, covers the compound, manufacturing methods and therapeutic uses and provides protection into 2035, unless extended.
The patents target treatment applications for metabolic and liver diseases, including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and diabetes, and support MetaVia's strategy to maximize long-term value for vanoglipel.
Positive
- 48 granted and pending patents worldwide
- Patent coverage extends into 2035, unless extended
- Exclusive license from Dong-A ST secures rights
Negative
- Protection limited to 2035 unless extensions granted
- Vanoglipel remains clinical-stage with no commercialization yet
Key Figures
Market Reality Check
Peers on Argus
MTVA is up 5.16% while peers are mixed: LPCN +9.77%, THAR +5.8%, PULM +0.91%, but PRTG -10.39% and SYBX -2.89%. Momentum scanner only flags LGVN -3.43%, reinforcing a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Investor forum appearance | Neutral | +3.2% | CEO scheduled to present obesity and metabolic therapy pipeline at virtual forum. |
| Feb 17 | Conference presentation | Neutral | -6.1% | Planned update on obesity and metabolic therapies at Emerging Growth Conference. |
| Feb 13 | IP expansion DA-1726 | Positive | -1.2% | Announced 39-patent IP portfolio for DA-1726 with protection into 2041. |
| Feb 04 | AI modeling results | Positive | -2.1% | AI collaboration identified key target pathways supporting vanoglipel focus on MASH and diabetes. |
| Jan 16 | Underwritten offering | Negative | -3.5% | Closed $9.3M offering with warrants to fund DA-1726 development and working capital. |
Recent history shows mixed trading around news. Positive clinical and IP updates (DA-1726, vanoglipel AI/clinical data) sometimes saw negative or muted reactions, while routine conference announcements produced both gains and declines. The January offering aligned with a negative price move. Overall, MTVA has not shown a consistent tendency to reward positive pipeline news in the short term, suggesting that financing and balance-sheet concerns may have weighed more heavily than scientific milestones in prior trading.
Over the last six months, MetaVia has balanced clinical progress with financing needs. On Jan 16, 2026, it closed a $9.3M underwritten offering tied to DA-1726 development, which coincided with a negative price reaction. Subsequent AI-modeling results for vanoglipel and an IP build-out for DA-1726 highlighted cardiometabolic and obesity pipelines but drew muted-to-negative trading. Multiple conference presentations in February–March 2026 focused on obesity and metabolic therapies. Today’s vanoglipel patent expansion extends that IP narrative specifically into metabolic and liver disease applications.
Market Pulse Summary
This announcement reinforces MetaVia’s strategy around vanoglipel by extending patent coverage into 2035 across 48 granted and pending patents in major markets. The IP spans composition, manufacturing, and uses in metabolic and liver diseases such as MASH and diabetes. In the context of earlier positive vanoglipel data, this helps secure potential commercial runway. Investors may watch how future clinical milestones, cash planning, and additional IP steps interact with this strengthened position.
Key Terms
g-protein-coupled receptor 119 medical
agonist medical
metabolic dysfunction-associated steatohepatitis medical
AI-generated analysis. Not financial advice.
Patent Portfolio Includes 48 Granted and Pending Patents in the
MetaVia's patent portfolio, exclusively licensed from Dong-A ST Co., Ltd., provides broad protection for vanoglipel itself, how it is manufactured, and its potential use across a range of serious metabolic and liver conditions. Collectively, the patents cover both the core compound and pharmaceutical compositions designed to treat diseases linked to metabolic dysfunction, including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and diabetes.
"Maintaining and expanding a strong intellectual property position is a core element of our strategy to maximize the long-term value potential of vanoglipel," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "These patents reflect the broad therapeutic opportunity for DA-1241 across liver and metabolic diseases and reinforce our commitment to advancing innovative oral treatments for patients who currently have limited options."
About Vanoglipel (DA-1241)
Vanoglipel (DA-1241) is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. Vanoglipel has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of vanoglipel has been demonstrated in multiple pre-clinical animal models of MASH and T2D where vanoglipel reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, vanoglipel was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's ability to execute on its commercial strategy; our expectations regarding the sufficiency of our existing cash on hand to fund our operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-expands-global-patent-protection-for-vanoglipel-supporting-metabolic-and-liver-disease-therapy-through-2035-302712075.html
SOURCE MetaVia Inc.
FAQ
What patent protection did MetaVia (MTVA) announce on March 12, 2026 for vanoglipel?
How long will MetaVia's (MTVA) vanoglipel patents provide protection?
What aspects of vanoglipel do MetaVia's (MTVA) patents cover?
Did MetaVia (MTVA) obtain the vanoglipel patents directly or via license?
What therapeutic areas does MetaVia (MTVA) target with vanoglipel?
What does the patent update mean for MetaVia (MTVA) investors?
